Compare Stocks → You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DBVTNASDAQ:FENCNASDAQ:MGTXNASDAQ:PROK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$0.69+1.5%$0.79$0.65▼$2.37$133.10M0.7550,278 shs19,220 shsFENCFennec Pharmaceuticals$9.57-1.3%$10.10$6.30▼$11.92$259.35M0.38110,783 shs159,643 shsMGTXMeiraGTx$5.01-4.6%$5.99$3.49▼$8.35$321.74M1.29154,734 shs235,243 shsPROKProKidney$2.40-15.5%$1.59$1.12▼$13.51$651.34M1.08652,910 shs1.51 million shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies+1.49%-1.41%-13.30%-16.86%-57.92%FENCFennec Pharmaceuticals-1.34%-11.63%-13.08%-4.40%+18.59%MGTXMeiraGTx-4.57%-12.57%-20.22%-18.14%-8.41%PROKProKidney-15.49%+46.34%+75.18%+84.62%-80.34%Now Open: Crypto emergency update (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDBVTDBV Technologies1.5414 of 5 stars3.21.00.00.00.63.31.3FENCFennec Pharmaceuticals2.3667 of 5 stars3.50.00.00.02.42.51.9MGTXMeiraGTx3.8605 of 5 stars3.54.00.04.80.01.70.6PROKProKidney1.4883 of 5 stars3.21.00.00.02.93.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDBVTDBV Technologies2.33Hold$5.00624.53% UpsideFENCFennec Pharmaceuticals3.00Buy$17.3381.12% UpsideMGTXMeiraGTx3.00Buy$25.67412.31% UpsidePROKProKidney2.33Hold$9.50295.83% UpsideCurrent Analyst RatingsLatest FENC, MGTX, PROK, and DBVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.003/7/2024PROKProKidneyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$3.002/21/2024DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDBVTDBV Technologies$15.73M8.46N/AN/A$0.73 per share0.95FENCFennec Pharmaceuticals$21.25M12.20N/AN/A($0.43) per share-22.26MGTXMeiraGTx$14.02M22.95N/AN/A$2.17 per share2.31PROKProKidneyN/AN/AN/AN/A($4.84) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDBVTDBV Technologies-$72.73M-$0.39N/AN/AN/A-461.32%-46.33%-35.32%5/2/2024 (Estimated)FENCFennec Pharmaceuticals-$16.05M-$0.61N/A13.67N/A-75.50%N/A-73.64%5/9/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.57N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)PROKProKidney-$35.47M-$0.57N/AN/AN/AN/AN/A-7.66%5/9/2024 (Estimated)Latest FENC, MGTX, PROK, and DBVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 million3/21/2024Q4 2023PROKProKidney-$0.19-$0.09+$0.10-$0.09N/AN/A3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million3/7/2024Q4 2023DBVTDBV Technologies-$0.16-$0.06+$0.10-$0.06$1.10 million$8.88 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDBVTDBV TechnologiesN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDBVTDBV TechnologiesN/A4.264.26FENCFennec PharmaceuticalsN/A3.563.27MGTXMeiraGTx0.622.382.38PROKProKidneyN/A14.9414.94OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDBVTDBV Technologies71.74%FENCFennec Pharmaceuticals55.51%MGTXMeiraGTx67.48%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipDBVTDBV Technologies0.71%FENCFennec Pharmaceuticals11.25%MGTXMeiraGTx9.70%PROKProKidney44.99%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDBVTDBV Technologies104192.87 million191.50 millionOptionableFENCFennec PharmaceuticalsN/A27.10 million24.06 millionOptionableMGTXMeiraGTx41964.22 million57.99 millionOptionablePROKProKidney163229.34 million126.16 millionOptionableFENC, MGTX, PROK, and DBVT HeadlinesSourceHeadlineProKidney (NASDAQ:PROK) Shares Gap Down After Insider Sellingamericanbankingnews.com - April 19 at 1:22 AMProKidney (NASDAQ:PROK) Shares Gap Down Following Insider Sellingmarketbeat.com - April 18 at 10:35 AMDarin J. Weber Sells 17,238 Shares of ProKidney Corp. (NASDAQ:PROK) Stockinsidertrades.com - April 18 at 6:49 AMProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber Sells 17,238 Sharesmarketbeat.com - April 17 at 9:22 PMProKidney (NASDAQ:PROK) Shares Gap Up to $2.72marketbeat.com - April 17 at 10:52 AMProKidney (NASDAQ:PROK) Sees Large Volume Increasemarketbeat.com - April 15 at 4:39 PMProKidney (NASDAQ:PROK) Trading 13.1% Higher americanbankingnews.com - April 12 at 2:00 AMProKidney adds two officials to executive-management teamjournalnow.com - March 26 at 1:12 AMDuring manufacturing pause, ProKidney increases R&D spending to $106.7Mbizjournals.com - March 26 at 1:12 AMProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operationsglobenewswire.com - March 25 at 6:05 AMBuy Rating Affirmed for ProKidney Amidst Strategic Clinical Advancements and Solid Financial Outlookmarkets.businessinsider.com - March 24 at 5:00 AMProKidney reports lower loss in 2023; manufacturing pause still onjournalnow.com - March 22 at 11:10 PMProKidney report lower loss in 2023; manufacturing pause still onjournalnow.com - March 22 at 6:10 PMProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlightsglobenewswire.com - March 21 at 7:49 PMProKidney (PROK) to Release Earnings on Fridaymarketbeat.com - March 21 at 7:37 AMProKidney discloses severance packages to former senior executivesjournalnow.com - March 19 at 10:07 PMProKidney assumed with an Equal Weight at Morgan Stanleyrealmoney.thestreet.com - March 7 at 9:14 AMProKidney to Participate in Jefferies Biotech on the Bay Summitglobenewswire.com - February 29 at 4:05 PMPROK Mar 2024 7.500 callfinance.yahoo.com - February 17 at 2:18 PMNorth Carolina biotech tops $400M in funding for asthma treatmentbizjournals.com - February 16 at 7:54 AMTriad falls back in high-profile Milken economic rankings; high-tech future looks brightjournalnow.com - February 11 at 9:31 AMProKidney (NASDAQ: PROK)fool.com - February 9 at 10:28 AMProKidney: Regulation Fd Disclosure, Financial Statements And Exhibitscbonds.com - January 28 at 9:31 AMProKidney enters agreement for potential sale of sharesjournalnow.com - January 22 at 8:32 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsDBV TechnologiesNASDAQ:DBVTDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.ProKidneyNASDAQ:PROKProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.